Data provided by Longhorn vaccine and diagnostics indicate that lhnvd-201 has neutralizing activity against covid-19 and influenza coinfection.

Appili Therapeutics a biodefense and infectious disease drug company, announced that its production and marketing partner, Saptalis Pharmaceuticals, received US FDA approval for Metronidazole Oral Suspension 500mg/5mL.

Nova Therapeutics, a biotech firm specializing in Influenza A treatments, received US FDA approval for its IND application for influenza A suppressant, VNT-101.

Merck reported that the phase III KEYNOTE-A39/EV-302 test halted disease progression in certain patients with local or metastatic urothelial cancer who hadn't received prior treatment.

Genmab Unveils EU Commission's Authorization for TEPKINLY® (epcoritamab) to Treat Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in Adults.

Lutathera®, a radioligand therapy by Novartis, showed significant progression-free survival rates in initial stage advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Shanghai Henlius Biotech, Inc. has made a public announcement that the NMPA has given approval to the NDA for an innovative fresh indication of HANSIZHUANG (serplulimab injection).

SELLAS reveals uplifting preliminary findings in Lymphoma group from SLS009 Phase 1 Increasing-Dose Study, promoting progression to Phase 2 Clinical Experiment.

Krystal Biotech publicized that the U.S. FDA has given the green light for the Investigational New Drug application for KB408 to manage alpha-1 antitrypsin deficiency.

Jazz Pharmaceuticals plc has proclaimed that the EC has approved the commercialization of Enrylaze®(JZP458; a derivative of Erwinia asparaginase or crisantaspase).

Leucid Bio announced today its UK MHRA-approved CTA to commence Phase 1/2 AERIAL clinical trials of its drug, LEU011, for treating adult patients with relapsed or resistant solid tumours.

Bristol Myers Squibb states that a pre/postoperative regimen of Opdivo (nivolumab) and chemotherapy significantly improves survival in operable non-small cell lung cancer patients.